| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3274969 | Médecine des Maladies Métaboliques | 2011 | 8 Pages |
Abstract
New therapeutic approaches to diabetes treatment based on the inhibition of glucagon action are being currently studied. It is needless to say that these approaches confirm the role of glucagon in the physiopathology of type 2 diabetes. Different strategies aimed to block glucagon effects are being explored: monoclonal antibodies to the human glucagon receptor (GR), antisense oligonucleotides, peptides and small-molecule antagonists for the glucagon receptor. Promising preclinical and clinical results are presented in this article.
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
D. Moller, C. Kazda, C. Cueille,